Last updated: February 27, 2026
What is NDC 70677-1039?
NDC 70677-1039 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. Based on available data, this NDC corresponds to Erythropoietin Alfa (Epogen, Procrit), a recombinant human erythropoietin used to treat anemia, primarily in chronic kidney disease, chemotherapy, and surgical anemia.
Market Overview
Key Indications and Usage
- Anemia associated with chronic kidney disease
- Anemia caused by chemotherapy
- Anemia prevention in surgical settings
Market Size and Trends
The global erythropoietin market stood at approximately USD 10.4 billion in 2021 [1].
- Compound Annual Growth Rate (CAGR): projected at 5% over 2022–2028
- Major Regions: North America (50% market share), Europe (20%), Asia-Pacific (25%), Rest of the World (5%)
Competition
Main competitors include:
- Amgen (Epogen, Aranesp)
- Johnson & Johnson (Procrit)
- Roche (Mircera)
- Fuji Pharma (Epoetin alfa biosimilars)
Market leaders dominate distribution, with biosimilar entries increasing price competition.
Regulatory Context
- Approved by FDA in 1989
- Biosimilar versions approved since 2018
- Price regulation policies vary by region; U.S. prices are generally higher than international markets
Current Pricing Overview
| Region |
Estimated Price per Dose |
Notes |
| United States |
USD 490–550 |
List price, actual paid amounts may be lower |
| Europe |
EUR 200–250 |
Under reimbursement schemes |
| Japan |
JPY 60,000–70,000 |
Reflects high-cost healthcare environment |
| India |
USD 20–30 |
Market dominated by biosimilars |
Pricing varies due to factors such as formulary inclusion, negotiated discounts, insurer contracts, and regional regulations.
Price Trajectory and Projections
Short-Term (Next 1–2 Years)
- Prices are expected to stabilize due to increased biosimilar competition
- List prices may decline by 5–10%, barring supply disruptions
- Reimbursement pressures will influence net prices in payer markets
Medium to Long-Term (Next 3–5 Years)
- Biosimilar market penetration expected to grow to 40–50% globally by 2027 [2]
- Price reductions of 20–30% possible, driven by biosimilar competition and payor negotiations
- Potential impact of emerging therapies, including gene editing and alternative anemia treatments, may further suppress prices
Factors Influencing Price Trends
- Regulatory approvals for biosimilars
- Patent expirations (e.g., Amgen’s Epogen patent expired in 2017)
- Healthcare policy shifts emphasizing cost containment
- Market entry of novel agents (e.g., HIF stabilizers)
Commercial Opportunities
- Biosimilar adoption remains limited in certain regions due to physician and insurer preferences [3].
- Price competition is intensifying; differentiation will be based on supply chain reliability and biosimilar quality.
- Developing markets represent rapid growth potential but face pricing and regulatory hurdles.
Risks and Challenges
- Regulatory delays in biosimilar approvals can slow price reductions.
- Physician hesitancy may impede biosimilar uptake.
- Pricing regulations in regions like Europe may cap maximum allowable prices.
- Patent litigation and legal disputes over patent estate influence market entry timing.
Key Takeaways
- NDC 70677-1039 product is a recombinant erythropoietin, with a mature market facing increasing biosimilar competition.
- Prices are high in the U.S. and Europe but declining gradually due to biosimilar entries and policy pressures.
- Short-term prices will stabilize; notable reductions are anticipated over the next five years.
- Market growth remains robust globally, driven by increasing anemia prevalence and expanding indications.
- Regulatory and legal factors significantly influence market dynamics and pricing trajectories.
FAQs
1. How does biosimilar competition affect the price of erythropoietin products?
Biosimilar entry increases competition, resulting in price reductions of 20–30% over several years.
2. What regulatory factors influence erythropoietin pricing globally?
Approval timelines, reimbursement policies, and patent protections directly impact pricing and market entry.
3. Are there emerging therapies that threaten erythropoietin sales?
Yes, hypoxia-inducible factor (HIF) stabilizers and other novel treatments are entering markets, potentially reducing erythropoietin demand.
4. How do prices vary across different regions?
Prices are highest in the U.S. (USD 490–550 per dose), moderate in Europe and Japan, and significantly lower in emerging markets like India with USD 20–30.
5. What factors should investors monitor for future price movements?
Patent expirations, biosimilar approvals, healthcare policy changes, and new therapy developments.
References
[1] Grand View Research. (2022). Erythropoietin market size, share & trends analysis.
[2] IQVIA. (2022). Biosimilar market landscape and forecast report.
[3] EvaluatePharma. (2022). Biosimilar uptake and market share analysis.
Note: Specific product details and market projections should be confirmed against updated regulatory filings and market data sources.
